Oxurion NV
XBRU:OXUR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.28
6
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OXUR stock under the Base Case scenario is 0.78 EUR. Compared to the current market price of 0.28 EUR, Oxurion NV is Undervalued by 64%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Oxurion NV
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for OXUR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Oxurion NV
Balance Sheet Decomposition
Oxurion NV
Current Assets | 1.5m |
Cash & Short-Term Investments | 119k |
Receivables | 1.4m |
Non-Current Assets | 3m |
PP&E | 171k |
Other Non-Current Assets | 2.8m |
Current Liabilities | 19.3m |
Accounts Payable | 5.5m |
Other Current Liabilities | 13.8m |
Non-Current Liabilities | 46k |
Long-Term Debt | 34k |
Other Non-Current Liabilities | 12k |
Earnings Waterfall
Oxurion NV
Revenue
|
84k
EUR
|
Cost of Revenue
|
-105k
EUR
|
Gross Profit
|
-21k
EUR
|
Operating Expenses
|
-7.3m
EUR
|
Operating Income
|
-7.4m
EUR
|
Other Expenses
|
-4m
EUR
|
Net Income
|
-11.4m
EUR
|
Free Cash Flow Analysis
Oxurion NV
EUR | |
Free Cash Flow | EUR |
OXUR Profitability Score
Profitability Due Diligence
Oxurion NV's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Oxurion NV's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
OXUR Solvency Score
Solvency Due Diligence
Oxurion NV's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
Oxurion NV's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OXUR Price Targets Summary
Oxurion NV
Dividends
Current shareholder yield for OXUR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
OXUR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 42 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
Contact
IPO
Employees
Officers
The intrinsic value of one OXUR stock under the Base Case scenario is 0.78 EUR.
Compared to the current market price of 0.28 EUR, Oxurion NV is Undervalued by 64%.